Keyphrases
Medullary Breast Carcinoma
100%
National Cancer Database
100%
Chemotherapy
57%
Overall Survival
57%
Colorectal Cancer
50%
Targeted Therapy
50%
Bone Metastasis
50%
Cancer Complications
50%
Simvastatin
50%
Brain Metastases
50%
Erlotinib
50%
Patients with Colorectal Cancer
50%
Pharmacologic
50%
Rhabdomyolysis
50%
Larval Arrest
50%
Vascular Endothelial Growth Factor
50%
Adult Longevity
50%
Atypical Medullary Carcinoma
50%
Cancer Management
50%
Monoclonal Antibody
50%
General Community
50%
Breast Carcinoma
50%
T2N0M0
50%
Tolerability
50%
Adult Behavior
50%
B-cell Malignancies
50%
Caenorhabditis Elegans
50%
Daf-2
50%
Center Experience
50%
Bruton Tyrosine Kinase Inhibitor
50%
Prognostic Factors
50%
Prognostic Survival
50%
Ibrutinib
50%
Adverse Effects
30%
Metastasis
28%
Growth Factor Pathway
25%
Clinical Activity
25%
Target Specificity
25%
Therapeutic Target
25%
Toxicity Characteristic
25%
Tumor Selectivity
25%
Epidermal Growth Factor Receptor
25%
Tumor-specific
25%
Biologic Effect
25%
Non-associated
25%
Inhibitory Antibody
25%
Statins
25%
Epidermal Growth Factor
25%
Targeted Therapeutics
25%
Antibody Inhibition
25%
Medicine and Dentistry
Malignant Neoplasm
100%
Base
100%
Neoplasm
96%
Overall Survival
57%
Side Effect
54%
Vasculotropin
50%
Bruton Tyrosine Kinase Inhibitor
50%
Targeted Therapy
50%
Cancer
50%
Medullary Carcinoma
50%
Prognostic Factor
50%
Monoclonal Antibody
50%
B Cell
50%
Ibrutinib
50%
Breast Carcinoma
50%
Breast Cancer
50%
Colorectal Carcinoma
50%
Epidermal Growth Factor
25%
Epidermal Growth Factor Receptor
25%
Biological Activity
25%
Comorbidity
21%
Adverse Effect
18%
Ductal Carcinoma
14%
Lymphocytosis
13%
Immunoglobulin
9%
Immunoglobulin A
9%
Atrial Fibrillation
9%
Breast Cancer Chemotherapy
8%
Rare Tumor
8%
Distant Metastasis
8%
Proportional Hazards Model
8%
Adjuvant Chemotherapy
8%
Hazard Ratio
8%
Propensity Score Matching
8%
Radiation Therapy
8%
Diseases
8%
Lymph Node
7%
Survival Rate
7%
Estrogen Receptor
7%
Hormone Therapy
7%
Quadrantectomy
7%
Progesterone Receptor
7%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
100%
Neoplasm
72%
Malignant Neoplasm
57%
Side Effect
54%
Chemotherapy
50%
Bruton Tyrosine Kinase Inhibitor
50%
Base
50%
Monoclonal Antibody
50%
Simvastatin
50%
Tolerability
50%
Rhabdomyolysis
50%
Ibrutinib
50%
Erlotinib
50%
Breast Cancer
50%
Vasculotropin
50%
Brain Metastasis
50%
Bone Metastasis
50%
Overall Survival
33%
Statin (Protein)
25%
Epidermal Growth Factor
25%
Epidermal Growth Factor Receptor
25%
Metastatic Colorectal Cancer
21%
Comorbidity
15%
Irinotecan
14%
Oxaliplatin
14%
Lymphocytosis
13%
Drug Interaction
12%
Non Small Cell Lung Cancer
12%
Epidermal Growth Factor Receptor Kinase Inhibitor
12%
CYP3A4
12%
Atrial Fibrillation
9%
Immunoglobulin A
9%
Immunoglobulin
9%
Fox
7%
Lung Metastasis
7%
Primary Tumor
7%
Systemic Treatment
7%
Colon Carcinoma
7%
Cancer Chemotherapy
5%
Distant Metastasis
5%
Diseases
5%